Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 to 75 years of age.~* Patients with a diagnosis of patch type alopecia areata.~* Patients will have \>30% and \<95% total scalp hair loss at baseline as measured using the SALT score. Two patients with current episodes of alopecia totalis/universalis may be included in this study.~* Duration of hair loss greater than 3 months.~* No evidence of regrowth present at baseline.~* Patients may be naïve to treatment or unresponsive to intralesional (IL) steroids or other treatments for alopecia areata.~Exclusion Criteria:~* Patients with a history of or active skin disease on the scalp such as psoriasis or seborrheic dermatitis.~* Patients in whom the diagnosis of alopecia areata is in question.~* Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma) that in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections.~* Women of childbearing potential who are unable or unwilling to use two forms of birth control for the study duration.~* Women who are pregnant or nursing.~* Patients known to be HIV or hepatitis B or C positive.~* Patients with history or evidence of hematopoietic abnormality.~* Patients with \<200K platelet count at baseline.~* Patients with history or evidence of renal or hepatic impairment.~* Patients with history of immunosuppression or history of recurrent serious infections.~* Patients unwilling or unable to discontinue treatments known to affect hair regrowth in AA.~* Patients taking any medication considered a strong CYP3A4 inhibitor who is unable or unwilling to stop this medication for the duration of the study.~* Patients receiving treatment deemed to affect alopecia areata within 2 weeks to one month of baseline visit depending on the specific treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.

Based on this trial design, predict the completion outcome and termination type (if applicable).